News

Due to the long duration of response, patients only needed further treatment every two months, the company said. In addition, preliminary results of a Phase I/II study in

Graceptor is a once-daily modified release formulation of Astellas’s Prograf (tacrolimus, twice-daily formulation). Tacrolimus works as an immunosuppressant by inhibiting activation of T-cell. Graceptor maintains its efficacy and

HealthMedia’s suite of interventions reportedly provides automated web-based coaching for wellness, disease management, behavioral health and medication adherence with proven outcomes, increased compliance, reduced medical utilization, and increased

AVE1642 was developed by ImmunoGen using the company’s expertise in monoclonal antibodies and cancer biology, and was humanized using ImmunoGen’s proprietary resurfacing technology. The compound was licensed to

Preliminary data from a Phase I single ascending dose study of RDEA594 in healthy volunteers showed that oral administration of 100mg of RDEA594 demonstrated a favorable pharmacokinetic profile

According to the company, AP24534 demonstrated potent inhibition of selected kinase targets that control tumor growth and angiogenesis, notably all four receptors for fibroblast growth factors (FGFRs). The

In connection with the transaction, Pacgen would acquire all of the issued and outstanding shares of Medigen by way of share purchase or through such other transaction structure

Results of the Radiate study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies, demonstrated that half of the patients treated with

Data presented demonstrate that a single administration of IPI-926 in a preclinical model of human pancreatic cancer results in rapid and sustained Hedgehog pathway inhibition in the stromal